Results 51 to 60 of about 233,497 (306)

Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells [PDF]

The Journal of Immunology, 2010
Abstract T cells gene-modified to express chimeric Ag receptors (CARs) have shown potent antitumor activity in vivo and are in clinical trials at locations worldwide. However, CAR activity has been investigated in mouse models in which Ag expression is restricted to the tumor.
Cheadle, Eleanor J., Hawkins, Robert E., Batha, Hayley, O'Neill, Allison L., Dovedi, Simon J., Gilham, David E.   +5 more
openaire   +2 more sources

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, Bitao Bu   +10 more
wiley   +1 more source

Multifunctional Neutrophil Nanovesicles Induce Remodeling of Tumor Immune Microenvironment and Synergistic Multimodal Tumor Therapy

Advanced Functional Materials, EarlyView.
Schematic illustration of the engineered RN@FDT for multimodal tumor therapy. a) Fabrication of FD&DOX/TFA‐loaded RGD‐NNV (RN@FDT) and the light‐triggered disassemble of RN@FDT. b) After internalized by tumor cells, RN@FDT are disintegrated under NIR‐II laser irradiation to boost PTT and induce cell apoptosis.
Jiahui Zhang, Cheng Ji, Xin‐Jian Fang, Yu Qian, Jiayuan Shi, Wenhui Liu, Baiyuan Fan, Yuan Zhong, Jiayi Wang, Dan Yu, Maoye Wang, Min Fu, Xiaoxin Zhang, Runbi Ji, Hélder A. Santos, Hongbo Zhang, Xu Zhang   +16 more
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression

Advanced Science, EarlyView.
A unique subset of CD9+ B cells regulates germinal center B (GC‐B) cell regression by inducing T follicular helper (Tfh) cell apoptosis through multiple signaling pathways, such as ALCAM‐CD6. FOXP1 plays a key role in GC‐B cell differentiation. These findings clarify mechanisms of GC degeneration and termination and offer potential targets for adenoid ...
Wenjing Liao, Lijuan Song, Meiqian Xu, Tianhao Liang, Yixuan Chen, Gui Chen, Zaihuan Lin, Huakang Du, Guofei Feng, Zhiming Feng, Qi Zhang, Fan Pan, Saixuan Yang, Xinyin Zhang, Wenxu Peng, Tianlong Li, Zhuoshen Lin, Yabang Chen, Jiayi Liu, Baoxin Peng, Yan Liu, Xing Niu, Ting Li, Chengyu Huang, Ke Mo, Jianlei Xie, Yu Zou, Xiaowen Zhang   +27 more
wiley   +1 more source

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity

Journal for ImmunoTherapy of Cancer, 2023
Background Hematologic toxicities, including coagulopathy, endothelial activation, and cytopenias, with CD19-targeted chimeric antigen receptor (CAR) T-cell therapies correlate with cytokine release syndrome (CRS) and neurotoxicity severity, but little ...
Hannah Smith, Haneen Shalabi, Bonnie Yates, Nirali N Shah, Hao-Wei Wang, Terry J Fry, Dong Chen, Kevin Parker, Martin Ongkeko, Yanyu Wang, Jennifer Jess, Alina Dulau-Florea, Jon Inglefield, Dan Lichtenstein, Fiorella Schischlik, Shilpa Shahani, Ann Cullinane, Eli Kane, Lauren Little, Ansuman Satpathy, Jay Lozier   +20 more
doaj   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Journal of Immunology Research, 2020
Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited.
Lichen Zhu, Xiaomei Yang, Dani Zhong, Shenxia Xie, Wei Shi, Yangzi Li, Xiaoqiong Hou, HuaYao, Huihui Zhou, Minlong Zhao, Ziqiang Ding, Xinyue Zhao, Fengzhen Mo, Shihua Yin, Aiqun Liu, Xiaoling Lu   +15 more
doaj   +1 more source

Modulation of the Bovine Delayed-Type Hypersensitivity Responses to Defined Mycobacterial Antigens by a Synthetic Bacterial Lipopeptide [PDF]

, 2003
The use of defined protein and peptide antigens can overcome specificity limitations of purified protein derivatives in the detection of bovine tuberculosis when the antigens are used in blood-based tests. Since the use of these specific antigens as skin
Howard, CJ, Hewinson, R. G., Vordermeier, H.M., Clifford, D., Hope, Jayne; id_orcid, Whelan, A O   +5 more
core  

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

, 2019
Immunotherapy with chimeric antigen receptor-engineered T-cells (CAR-T) is under investigation in multiple myeloma. There are reports of myeloma remission after CD19 CAR-T therapy, although CD19 is hardly detectable on myeloma cells by flow cytometry (FC)
Nerreter, Thomas, Sauer, Markus, Hudecek, Michael, Doose, Sören, Danhof, Sophia, Götz, Ralph, Letschert, Sebastian, Einsele, Hermann   +7 more
core   +1 more source